Lemaitre Vascular (LMAT) Misses Q3 EPS by 3c; Offers FY22 Guidance

Lemaitre Vascular (NASDAQ: LMAT) reported Q3 EPS of $0.25, $0.03 worse than the analyst estimate of $0.28. Revenue for the quarter came in at $39 million versus the consensus estimate of $40.06 million.

GUIDANCE:

Lemaitre Vascular sees FY2022 EPS of $1.02-$1.08, versus the consensus of $1.09. Lemaitre Vascular sees FY2022 revenue of $160.5-162.9 million, versus the consensus of $163.6 million.

For earnings history and earnings-related data on Lemaitre Vascular (LMAT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c